Recent progress in developing ATR inhibitors as anticancer agents

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• DNA damage response (DDR) pathways are essential for maintaining genome stability.
• The ataxia telangiectasia mutated and Rad3-related (ATR) kinase is a key regulator of DDR, responding to DNA damage and replication stress.
• ATR plays a critical role in cell cycle checkpoint control, initiating DNA repair processes.

Purpose of the Study:

• To review current ATR inhibitors and their structural optimization strategies.
• To analyze structure-activity relationships, biological activity, binding modes, and pharmacokinetic properties of ATR inhibitors.
• To discuss recent clinical advancements and future challenges in ATR inhibitor development for cancer treatment.

Main Methods:

• Literature review of published ATR inhibitors.
• Analysis of structure-activity relationships (SAR) and ligand binding modes.
• Evaluation of biological activity, pharmacokinetic properties, and clinical trial data.

Main Results:

• Numerous ATR inhibitors have been developed, showing potent antitumor effects alone and synergistically with other therapies.
• Structural optimization has led to improved potency and selectivity.
• Clinical evaluation of specific ATR inhibitors is ongoing, with promising preliminary results.

Conclusions:

• ATR inhibitors represent a promising therapeutic strategy for cancer treatment.
• Understanding SAR and PK properties is crucial for designing next-generation ATR inhibitors.
• Further clinical research is needed to overcome challenges and optimize the use of ATR inhibitors in oncology.